DiaMedica Therapeutics Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for DMAC, updated each market day.
DMAC AI Sentiment
AI sees no strong directional signal for DiaMedica Therapeutics Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Sector
Exchange
Market Cap
$332,993,887
Cap Tier
Employees
35
Headquarters
MINNEAPOLIS, MN
Listed Since
Nov. 29, 2007
Website
DMAC Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
DMAC Volatility
DiaMedica Therapeutics Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
